Novel insights into beta cell ER stress CHOP and its role in HFpEF development.

对β细胞内质网应激CHOP及其在HFpEF发展中的作用的新见解

阅读:13
作者:Srinivas Balaji, Fortuno Paula, Peng Hongmei, Xu Jiang, Suhail Hamid, Sabbah Hani N, Rhaleb Nour-Eddine, Matrougui Khalid
INTRODUCTION: Heart failure with preserved ejection fraction (HFpEF) is a multifactorial cardiovascular disorder characterized by diastolic dysfunction and often associated with hypertension and metabolic disturbances. We aimed to determine the inter-relationship between C/EBP homologous protein (CHOP) in b-cells and HFpEF development. METHODS: Eight-week-old male mice b-cell(flox/flox) and b-cell(CHOP-/-) were randomly divided into four groups: control b-cell(flox/flox) and b-cell(CHOP-/-) mice subjected to standard diet and water. b -cell(flox/flox) and b-cell(CHOP-/-) mice fed a high-fat diet (HFD) and L-NAME (0.5 g/L) for five weeks. A comprehensive cardiovascular, metabolic, and histological evaluation was conducted. RESULTS: Following five weeks of HFD and L-NAME, b-cell(flox/flox) mice exhibited clinical and molecular manifestations of HFpEF. These include diastolic dysfunction, a normal cardiac ejection fraction, hypertension, metabolic disorders, cardiac hypertrophy with fibrosis, pulmonary edema, renal injury, and reduced exercise tolerance. Vascular endothelial dysfunction was also observed. Western blot analysis showed a reduced phosphorylated endothelial nitric oxide synthase in mesenteric resistance arteries (MRA), concomitant with qRT-PCR data revealing elevated inflammatory and unfolded protein response markers in MRA, heart, and pancreas. Interestingly, b-cell(CHOP-/-) mice subjected to an HFD and L-NAME were protected from HFpEF and its associated pathologies. These mice displayed improved cardiac and vascular endothelial function, exercise tolerance, and reduced unfolded protein response and inflammatory factors compared to their b-cell(flox/flox). CONCLUSION: Our research indicates that deleting the unfolded protein response CHOP in b-cells has a robust cardiovascular protective effect against HFpEF pathogenesis. Therefore, targeting CHOP in b-cells is a promising lead for HFpEF pathogenesis therapy.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。